Clinical Research Directory

Inclusion Criteria: * Male and female aged 18-75 years old. The subjects must have informed consent to the study, and signed the written informed consent voluntarily. * Diagnosis as non resectable local advanced or metastatic pancreatic cancer by histology or cytology. * Measurable disease as defined by RECIST 1.1. * Without systemic treatment for pancreatic cancer. * ECOG physical strength score 0-2 * Estimated survival time \>=3 months. * The adequate bone marrow fuction and coagulation function Exclusion Criteria: * Known allergy or hypersensitivity to any components of the investigational drug product. * Previous treatment with highly selective inhibitors targeting Colony Stimulating Factor 1 (CSF-1)/Colony Stimulating Factor 1 Receptor (CSF-1R). * With Breast Cancer Gene 1/2 (BRCA1/2) gene mutation. * With a history of other malignancies within 5 years. * During the trial, other chemotherapy, targeted therapy, hormone therapy, immunotherapy, radiotherapy (except for local symptomatic radiotherapy) or traditional Chinese medicine must be used for anti-tumor treatment. * With conditions that significantly affected the absorption of oral drug. * Surgical treatment is required within 4 weeks before the first administration, or unhealed, infected, or dehiscence of previous surgical wounds. * During the 2 weeks prior to the first administration of this study, the patient was receiving chronic systemic steroid treatment or any other form of immunosuppressive treatment. * Concomitant use of strong inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4) within 14 days prior to randomization. * Previous peripheral neuropathy \> grade 1 (Common Terminology Criteria for Adverse Events, version 5.0). * Diagnosed with immune deficiency or interstitial lung disease. * The patients were vaccinated within 4 weeks before the first treatment. * Participated in any drug clinical trial within 4 weeks before the first treatment. * Active central nervous system (CNS) metastases. * Impaired cardiac function or clinically significant cardiac disease. * Known active liver or biliary disease, or other diseases that may lead to abnormal liver function test results during the study. * Known active infections from certain viruses, bacteria or parasites. * Patients with refractory/uncontrolled ascites or pleural effusion. * Pregnant or lactating women. * Any other clinically significant comorbidities, which in the judgment of the Investigator, should not be included.